Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13058559 | 0.77 | PTGDR2 (0.38) | MEN1KMT2AKDM4EALDH1A1PTGDR2 | |
| SCHEMBL3254228 | 0.77 | PTGDR2 (0.38) | MEN1KMT2AKDM4EALDH1A1PTGDR2 | |
| SCHEMBL13058564 | 0.77 | PTGDR2 (0.38) | MEN1KMT2AKDM4EALDH1A1PTGDR2 | |
| SCHEMBL13058568 | 0.76 | — | — | |
| SCHEMBL13058563 | 0.76 | PTGDR2 (0.37) | MEN1KMT2AKDM4EALDH1A1PTGDR2 | |
| SCHEMBL13058433 | 0.71 | GLA (0.37) | GLALMNA | |
| SCHEMBL6727699 | 0.64 | ACACB (0.42) | KMT2ALMNA | |
| SCHEMBL13058566 | 0.64 | ADAMTS5 (0.30) | — | |
| SCHEMBL13058571 | 0.63 | CRHR1 (0.31) | — | |
| SCHEMBL13058522 | 0.63 | POLB (0.31) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188294-B1 | TRICYCLIC BRIDGED CYCLOPENTANEDIONE DERIVATIVES AS HERBICIDES | SYNGENTA LTD (GB) | 2015-03-18 | — | — | EP | disclosed |
| US-8530667-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-8530667-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-20100298140-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298140-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| WO-2009030450-A2 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298140-A1 | NOVEL HERBICIDES | DDT, CYP1B1, CYP1A1 | MEN1 4244/4885KMT2A 726/4885KDM4E 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.